Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinoma
Not Applicable
- Conditions
- Pulmonary sarcomatoid carcinoma
- Registration Number
- JPRN-UMIN000046002
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 124
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients who chose not to participate in the study (2)Patients who received ICI as previous therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Response Rate, Progression Free Survival
- Secondary Outcome Measures
Name Time Method